AADI vs. PRQR, HURA, DMAC, ACIU, IKT, ESPR, DERM, NBTX, FDMT, and ENGN
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), DiaMedica Therapeutics (DMAC), AC Immune (ACIU), Inhibikase Therapeutics (IKT), Esperion Therapeutics (ESPR), Journey Medical (DERM), Nanobiotix (NBTX), 4D Molecular Therapeutics (FDMT), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.
Aadi Bioscience vs.
ProQR Therapeutics (NASDAQ:PRQR) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.
ProQR Therapeutics has higher earnings, but lower revenue than Aadi Bioscience. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
ProQR Therapeutics has a net margin of -134.31% compared to Aadi Bioscience's net margin of -246.06%. ProQR Therapeutics' return on equity of -71.58% beat Aadi Bioscience's return on equity.
ProQR Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
ProQR Therapeutics received 328 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 62.20% of users gave ProQR Therapeutics an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote.
In the previous week, ProQR Therapeutics had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for ProQR Therapeutics and 2 mentions for Aadi Bioscience. ProQR Therapeutics' average media sentiment score of 0.20 beat Aadi Bioscience's score of -0.47 indicating that ProQR Therapeutics is being referred to more favorably in the media.
ProQR Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 365.12%. Aadi Bioscience has a consensus price target of $1.67, suggesting a potential downside of 16.25%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than Aadi Bioscience.
32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
ProQR Therapeutics beats Aadi Bioscience on 14 of the 19 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:AADI) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy AADI Stock Free AADI Stock Alerts